Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUPI REDUCE
NCT06004986Phase 4Active, not recruiting
- Sponsor
- University of Amsterdam
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by University of Amsterdam. Started Aug 2023; status: active, not recruiting.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06004986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004986.